Alveus Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $160M
Overview
A biopharma company creating targeted inhaled therapeutics for severe lung diseases.
RespiratoryPulmonology
Technology Platform
A proprietary inhaled drug delivery platform that creates optimized formulations for deep lung targeting and sustained local drug activity.
Funding History
1Total raised:$160M
Venture$160M
Opportunities
Potential to establish a new treatment paradigm for pulmonary fibrosis and other severe lung diseases through targeted, local delivery.
Risk Factors
Technical challenges in achieving consistent and effective lung deposition in patients, and the high clinical development risk for novel IPF therapies.
Competitive Landscape
Competes with other biotechs focused on inhaled therapies for fibrosis, and must demonstrate superiority over standard-of-care systemic drugs.